ALAllison S. Limpert

Allison S. Limpert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Allison S. Limpert has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Aleshin

    Center for Therapeutics Discovery, Cancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

    1 shared publication
  • Carina D. Wimer

    Center for Therapeutics Discovery, Cancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

    1 shared publication
  • David A. Scott

    Cancer Metabolism Core, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

    1 shared publication
  • Douglas J. Sheffler

    Center for Therapeutics Discovery, Cancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

    1 shared publication
  • Fabiana Izidro Layng

    Center for Therapeutics Discovery, Cancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

    1 shared publication
  • Jeffrey W. Smith

    Center for Therapeutics Discovery, Cancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

    1 shared publication

Latest Publications

  • Open Access

    Reversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase

    by Joseph Fromm, Alexander Aleshin, Lester J. Lambert, Laurent J. S. De Backer, Santhi Reddy Ganji, Margrith E. Mattmann, Allison S. Limpert, Palak Gosalia, Carina D. Wimer, Fabiana Izidro Layng, et al.

    Fatty acid synthase (FASN) is the sole enzyme capable of lipogenesis in cells and is upregulated in many cancers. Herein we report the discovery and development of SBP-5917 ( 78S ), a novel, reversible, small-molecule probe which targets the thioesterase (TE) domain of FASN. SBP-5917 and other compounds in the series possess IC 50 < 1 µM and < 5 µM for inhibiting recombinantly purified FASN-TE and cellular FASN respectively. Co-crystal structures of our inhibitors bound to the FASN-TE domain show that they are positioned in the substrate tunnel of the enzyme. Biochemical and biophysical analyses quantify the strength of compound binding and demonstrate their selectivity for FASN-TE. Preliminary pharmacokinetic studies indicate promising in vivo potency for many of the compounds in the series. SBP-5917 is the first structurally validated, reversible inhibitor of FASN-TE with demonstrated cellular target engagement and can serve as a chemical probe to investigate FASN as a therapeutic target. ABSTRACT FIGURE: